Bone Marrow Suppression in the Setting of Normal Thiopurine Methyltransferase Phenotype Testing

Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology . 2004;126:1504-1517.

Kishikawa H. , Nishida J. , Nakano M. , Hirano E. , Morishita T. , Ishii H. Ulcerative colitis associated with aplastic anemia. Dig Dis Sci. 2003;48:1376-1379.

Sharma BC , Yachha SK , Mishra RN , Gupta D. Hypoplastic anemia associated with ulcerative colitis in a child. J Pediatr Gastroenterol Nutr. 1996;23:326-328.

Sandborn WJ A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol . 1996;91:423-433.

de Boer NK , Derijks LJ , Gilissen LP , et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol. 2005;11:5540-5544.

Kirschner BS Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology . 1998;115:813-821.

Abeloff MD , ed. Clinical Oncology. 3rd ed. Philadelphia, PA: Churchill Livingstone; 2004:534.

Gearry RB , Barclay ML Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20: 1149-1157.

Frohman EM , Havrdova E. , Levinson B. , Slanar O. Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms. Mult Scler. 2006;12:108-111.

Present DH , Meltzer SJ , Krumholz MP , Wolke A. , Korelitz BI 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111:641-649.

Connell WR , Kamm MA , Ritchie JK , Lennard-Jones JE Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut. 1993;34: 1081-1085.

Bernstein CN , Artinian L. , Anton PA , Shanahan F. Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity. Dig Dis Sci. 1994;39:1638-1641.

Colombel JF , Ferrari N. , Debuysere H. , et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy. Gastroenterology. 2000 ;118:1025-1030.

Kader HA , Wenner WJ Jr , Telega GW , Maller ES , Baldassano RN Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol. 2000;30:409-413.

Sies C. , Florkowski C. , George P. , et al. Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine. N Z Med J. 2005;118:U1324.

Kotanagi H. , Ito M. , Koyama K. , Chiba M. Pancytopenia associated with 5-aminosalicylic acid use in a patient with Crohn’s disease. J Gastroenterol . 1998;33:571-574.

Casellas, F. , Vallano A. , Malagelada JR Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories. J Clin Gastroenterol. 1996;22:160-161.

Wyatt S. , Joyner MV , Daneshmend TK Filgrastim for mesalazine-associated neutropenia. Lancet. 1993;341: 1476.

de Boer NK , Wong DR , Jharap B. , et al. Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol. 2007;102:2747-2753.

Dewit O. , Vanheuverzwyn R. , Desager JP , Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease. Aliment Pharmacol Ther . 2002;16:79-85.

Szumlanski CL , Weinshilboum RM Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine . Br J Clin Pharmacol. 1995;39: 456-459.

Lewis LD , Benin A. , Szumlanski CL , et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther. 1997;62:464-475.